[144] GE HealthCare Technologies Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for GE HealthCare Technologies Inc. (GEHC) discloses a proposed sale of 19,524 common shares through UBS Financial Services on 09/22/2025 on NASDAQ with an aggregate market value of $1,453,773. The filing lists the outstanding share count as 456,562,037. The shares were acquired through restricted stock vesting in four tranches between 09/01/2024 and 09/01/2025, totaling the listed units. The filer also reported a prior sale by Kenneth Stacherski of 11,757 shares on 09/12/2025 for gross proceeds of $905,590. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.

Positive

• Transparent disclosure of broker, sale date, share count, and aggregate market value
• Detailed acquisition history showing restricted stock vesting dates and units

Negative

• Insider liquidity: proposed sale plus a recent sale of 11,757 shares could be noted by investors
• No trading-plan date disclosed (no 10b5-1 adoption date provided in the filing)

Insights

Securities Analyst

TL;DR: Routine Rule 144 sale of vested restricted shares; disclosed quantities and values; no new operational or financial facts presented.

The filing documents a planned disposition of 19,524 common shares via UBS on NASDAQ for $1,453,773, consistent with sales of vested restricted stock. The breakdown of acquisition dates shows multiple vesting events between 09/01/2024 and 09/01/2025, indicating these are compensation-related holdings being monetized. The prior reported sale of 11,757 shares for $905,590 on 09/12/2025 provides recent execution context. This is a compliance-driven disclosure under Rule 144 rather than a corporate event affecting GEHC's operations. For investors, the filing signals insider liquidity but does not reveal undisclosed material information about the issuer.

Corporate Governance Expert

TL;DR: Transparent insider sale reporting aligns with governance norms; attestation about material information is included.

The notice meets disclosure expectations by identifying the broker, dates, share counts, and acquisition method (restricted stock vesting). Inclusion of the seller’s attestation that no undisclosed material adverse information exists is standard and important for compliance. The filing does not indicate a trading plan date or 10b5-1 details. From a governance standpoint, the record shows routine insider monetization rather than a governance concern, but investors may track aggregate insider dispositions over time for broader context.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	19524	1453773	456562037	09/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2024	Restricted Stock Vest	GE HealthCare Technologies Inc.			1185	09/22/2025	NA
Common	11/01/2024	Restricted Stock Vest	GE HealthCare Technologies Inc.			15137	09/22/2025	NA
Common	02/01/2025	Restricted Stock Vest	GE HealthCare Technologies Inc.			895	09/22/2025	NA
Common	09/01/2025	Restricted Stock Vest	GE HealthCare Technologies Inc.			2307	09/22/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kenneth Stacherski 500 W. Monroe Street Chicago IL 60661	Common Shares	09/12/2025	11757	905590

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares is GEHC insider proposing to sell on 09/22/2025?

The filing proposes selling 19,524 common shares through UBS on NASDAQ with an aggregate market value of $1,453,773.

How were the shares being sold acquired?

The shares were acquired through restricted stock vesting in four tranches between 09/01/2024 and 09/01/2025.

Did the filer report any sales in the past three months?

Yes. Kenneth Stacherski sold 11,757 shares on 09/12/2025 for gross proceeds of $905,590.

Which broker will execute the proposed sale?

The proposed sale lists UBS Financial Services Inc as the broker at the specified address.

Does the filing state any undisclosed material information about GEHC?

No. The filing includes the seller’s attestation that they are not aware of any undisclosed material adverse information regarding the issuer.